SCILEX HOLDING CO SCLX
COM · Common Stock · CUSIP 80880W106
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersPalo Alto, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.33.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2022 | 8 |
| Q1 2023 | 88 |
| Q2 2023 | 94 |
| Q3 2023 | 83 |
| Q4 2023 | 92 |
| Q1 2024 | 103 |
| Q2 2024 | 91 |
| Q3 2024 | 94 |
| Q4 2024 | 102 |
| Q1 2025 | 80 |
| Q2 2025 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2023 | 28 | 35 |
| Q4 2023 | 33 | 17 |
| Q1 2024 | 46 | 21 |
| Q2 2024 | 26 | 42 |
| Q3 2024 | 28 | 19 |
| Q4 2024 | 35 | 22 |
| Q1 2025 | 24 | 40 |
| Q2 2025 | 0 | 78 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2024 | $426.9k | $58.3k | 0.14 |
| Q4 2024 | $38.6k | $32.3k | 0.84 |
| Q1 2025 | $6.2k | $2.8k | 0.45 |
| Q2 2025 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| ARMISTICE CAPITAL, LLC | Sold out | -13.8m |
| STATE STREET CORP | Sold out | -7.6m |
| BlackRock, Inc. | Sold out | -6.7m |
| VANGUARD GROUP INC | Sold out | -5.9m |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -1.6m |
| NORTHERN TRUST CORP | Sold out | -1.3m |
| RA CAPITAL MANAGEMENT, L.P. | Sold out | -1.0m |
| UBS Group AG | Sold out | -731.5k |
| D. E. Shaw & Co., Inc. | Sold out | -627.0k |
| Rafferty Asset Management, LLC | Sold out | -620.1k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
SCLX Stock Acquisition JV LLC
13D · may seek influence
-1.7 pts · filed 2025-01-23
Stated purposeItem 4 of the Schedule 13D is hereby amended and supplemented as follows: Romeg License Amendment On January 16, 2025, the Issuer entered into a First Amendment to License and Commercialization Agreement (the "License Amendment") with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC ("Romeg") to amend a previously executed license agreement. In consideration of the execution of the License Amendment, and as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of Common Stock, held by the Reporting Person. Amendment to Senior Secured Promissory Note As previously disclosed by the Issuer, the Issuer issued a Senior Secured Promissory Note, dated as of September 21, 2023, t… Full filing |
21.1% |
| ORAMED PHARMACEUTICALS INC. 13G · passive investor +3.7 pts · filed 2025-05-08 | 9.9% |
Insider purchases and sales in Q2 2025
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2023 | 0 | — | 0 | — | — |
| Q4 2023 | 0 | — | 0 | — | — |
| Q1 2024 | 0 | — | 0 | — | — |
| Q2 2024 | 4 | $230.3k | 0 | — | — |
| Q3 2024 | 0 | — | 0 | — | — |
| Q4 2024 | 7 | $126.3k | 0 | — | — |
| Q1 2025 | 0 | — | 0 | — | — |
| Q2 2025 | 0 | — | 0 | — | — |
None reported in Q2 2025.
Holders, Q2 2025
| Manager | Shares | Change |
|---|---|---|
| AMALGAMATED BANK 0.00% of their portfolio | 3.0k $1.0k | Unchanged |